Skip to main content

Advertisement

SpringerLink
Log in

Risk and prognosis of secondary breast cancer after radiation therapy for non-Hodgkin lymphoma: a massive population-based analysis

  • RESEARCH ARTICLE
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

One of the best ways to control non-Hodgkin lymphoma (NHL) locally is radiation therapy (RT), which is a crucial component of care for many patients. There has not been any research on the risk and prognosis of secondary breast cancer (SBC) in females with NHL receiving RT.

Methods

In our study, females with NHL as their initial cancer diagnosis were included from 1975 to 2018 in the Surveillance, Epidemiology and End Results (SEER) database. Using Fine and Gray's competing risk regression assess the cumulative incidence of SBC. The standardized incidence ratios (SIR) and radiation-attributed risk (RR) for SBC were assessed using Poisson regression analysis. We evaluated the overall survival (OS) of SBC patients using the Kaplan–Meier technique.

Results

Of the 41,983 females with NHL, 10,070 received RT and 320 (3.18%) developed SBC. 31,913 females did not receive RT and 805 (2.52%) developed SBC. RT was significantly related with a greater chance of acquiring SBC in the Fine-Gray competing risk regression (adjusted hazard ratios (HR) = 1.14; 95% confidence intervals (CI), 1.09–1.30; P = 0.011). When an NHL diagnosis was made at an older age, the dynamic SIR and RR for SBC also declined over time. Regarding general survivability, there was not statistically significant (P = 0.970) after propensity score matching (PSM).

Conclusions

RT is an independent risk factor for SBC in females with NHL. Special attention should be paid to the monitoring of breast cancer indicators in them, especially young.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Pianko MJ, Moskowitz AJ, Lesokhin AM. Immunotherapy of lymphoma and myeloma: facts and hopes. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(5):1002–10.

    Article  CAS  Google Scholar 

  2. van de Schans SA, Gondos A, van Spronsen DJ, Rachtan J, Holleczek B, Zanetti R, et al. Improving relative survival, but large remaining differences in survival for non-Hodgkin’s lymphoma across Europe and the United States from 1990 to 2004. J Clin Oncol. 2011;29(2):192–9.

    Article  PubMed  Google Scholar 

  3. Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123(17):3326–34.

    Article  PubMed  Google Scholar 

  4. Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668–76.

    Article  PubMed  Google Scholar 

  5. Chattopadhyay S, Zheng G, Sud A, Sundquist K, Sundquist J, Försti A, et al. Second primary cancers in non-Hodgkin lymphoma: Family history and survival. Int J Cancer. 2020;146(4):970–6.

    Article  CAS  PubMed  Google Scholar 

  6. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol. 2010;28(33):4935–44.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lorenzo Bermejo J, Pukkala E, Johannesen TB, Sundquist J, Hemminki K. Age-time risk patterns of solid cancers in 60 901 non-Hodgkin lymphoma survivors from Finland. Nor Swed Br J Haematol. 2014;164(5):675–83.

    Article  Google Scholar 

  8. Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017;178(1):72–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Li J, Peng F, Huang H, Cai Z. Trends in the risk of second primary malignances after non-Hodgkin’s lymphoma. Am J Cancer Res. 2022;12(6):2863–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Chattopadhyay S, Sud A, Zheng G, Yu H, Sundquist K, Sundquist J, et al. Second primary cancers in non-Hodgkin lymphoma: Bidirectional analyses suggesting role for immune dysfunction. Int J Cancer. 2018;143(10):2449–57.

    Article  CAS  PubMed  Google Scholar 

  11. Zimmermann M, Oehler C, Mey U, Ghadjar P, Zwahlen DR. Radiotherapy for Non-Hodgkin’s lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol (London, England). 2016;11(1):110.

    Article  Google Scholar 

  12. Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.

    Article  PubMed  Google Scholar 

  13. Michalski JM, Yan Y, Watkins-Bruner D, Bosch WR, Winter K, Galvin JM, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. Int J Radiat Oncol Biol Phys. 2013;87(5):932–8.

    Article  PubMed  Google Scholar 

  14. Yeboa DN, Evans SB. Contemporary breast radiotherapy and cardiac toxicity. Semin Radiat Oncol. 2016;26(1):71–8.

    Article  PubMed  Google Scholar 

  15. Schmid MP, Pötter R, Bombosch V, Sljivic S, Kirisits C, Dörr W, et al. Late gastrointestinal and urogenital side-effects after radiotherapy–incidence and prevalence Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2012;104(1):114–8.

    Article  Google Scholar 

  16. Molenaar RJ, Sidana S, Radivoyevitch T, Advani AS, Gerds AT, Carraway HE, et al. Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol. 2018;36(18):1831–9.

    Article  CAS  PubMed  Google Scholar 

  17. Guan X, Wei R, Yang R, Lu Z, Liu E, Zhao Z, et al. Risk and prognosis of secondary bladder cancer after radiation therapy for rectal cancer: a large population-based cohort study. Front Oncol. 2020;10: 586401.

    Article  PubMed  Google Scholar 

  18. Rossi C, Jégu J, Mounier M, Dandoit M, Colonna M, Daubisse-Marliac L, et al. Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. Leuk Lymphoma. 2015;56(10):2876–82.

    Article  PubMed  Google Scholar 

  19. Chien SH, Liu CJ, Hong YC, Teng CJ, Hu YW, Ku FC, et al. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study. J Cancer Res Clin Oncol. 2015;141(11):1995–2004.

    Article  CAS  PubMed  Google Scholar 

  20. Chien SH, Liu CJ, Hu YW, Hong YC, Teng CJ, Yeh CM, et al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study. Int J Cancer. 2015;137(3):658–65.

    Article  CAS  PubMed  Google Scholar 

  21. Attarbaschi A, Carraro E, Ronceray L, Andrés M, Barzilai-Birenboim S, Bomken S, et al. Second malignant neoplasms after treatment of non-Hodgkin’s lymphoma-a retrospective multinational study of 189 children and adolescents. Leukemia. 2021;35(2):534–49.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No grant support.

Author information

Authors and Affiliations

  1. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

    Xiaoyan Lv & Fuling Zhou

  2. National Quality Control Center for Donated Organ Procurement, Hubei Key Laboratory of Medical Technology on Transplantation, Hubei Clinical Research Center for Natural Polymer Biological Liver, Hubei Engineering Center of Natural Polymer-Based Medical Materials, Transplant Center of Wuhan University, Institute of Hepatobiliary Diseases of Wuhan University, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China

    Pengpeng Yue

Authors
  1. Xiaoyan Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pengpeng Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fuling Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fuling Zhou.

Ethics declarations

Conflict of interest

None of the authors have any conflict of interest.

Ethical approval

Since the data were de-identified and available to the public, the current study did not require ethics committee permission.

Informed consent

For this type of study，formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lv, X., Yue, P. & Zhou, F. Risk and prognosis of secondary breast cancer after radiation therapy for non-Hodgkin lymphoma: a massive population-based analysis. Clin Transl Oncol 25, 1307–1314 (2023). https://doi.org/10.1007/s12094-022-03026-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-022-03026-z

Keywords

Search

Navigation